Related Experiment Video
Updated: Mar 8, 2026

Myocardial Infarction in Neonatal Mice, A Model of Cardiac Regeneration
Published on: May 24, 2016
Tissue plasminogen activator for neonatal coronary thrombosis presenting with mitral valve regurgitation and impaired
Delaram Molkara1, Jose A Silva Sepulveda1, Thomas Do1
1Rady Children's Hospital, San Diego, University of California, San Diego, California, USA.
Objective:
Neonatal coronary thrombosis is a rarely reported disorder, with variable outcomes described. This study assessed the feasibility and safety of an institutional protocol using tissue plasminogen activator (tPA) administration for the treatment of neonatal coronary artery thrombi.
Methods:
They reviewed the outcome of three neonates with clinical evidence of myocardial infarction secondary to coronary thrombosis. All three underwent the tPA treatment protocol.
Results:
The three described cases presented at 5 hours, 15 hours, and 10 days of life. The patients identified underwent the tPA protocol at least once. There was clinical evidence of improvement in coronary flow, as well as demonstration of increased left ventricular function and decreased mitral regurgitation. No major adverse events occurred.
Conclusion:
Thrombolytic therapy with this tPA protocol may be safe and effective in treating neonates with coronary thrombosis.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care

